Burning Rock Biotech Ltd
For the period ended Nov 20, 2025. Filed Nov 20, 2025.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Nov 20, 2025 · Filed Nov 20, 2025
Use the contents to explore the available documents and sections.
BNR$13.42+1.3%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Selected Financial Data
Selected Financial Data
| For the three months ended · For the nine months ended | ||||
|---|---|---|---|---|
| Revenues | September30, 2024 | September 30,2025 | September 30,2024 | September 30,2025 |
| (RMB in thousands) · (RMB in thousands) | ||||
| Central laboratory channel | 39,984 | 36,811 | 136,371 | 115,968 |
| In-hospital channel | 63,769 | 52,847 | 181,028 | 173,030 |
| Pharma research and development channel | 24,891 | 41,959 | 72,401 | 124,255 |
| Total revenues | 128,644 | 131,617 | 389,800 | 413,253 |
| For the three months ended · For the nine months ended | ||||
|---|---|---|---|---|
| Revenues by location of customer | September30, 2024 | September 30,2025 | September 30,2024 | September 30,2025 |
| (RMB in thousands) · (RMB in thousands) | ||||
| Overseas | 25,840 | 17,214 | 59,553 | 79,079 |
| Mainland China | 102,804 | 114,403 | 330,247 | 334,174 |
| Total Revenues | 128,644 | 131,617 | 389,800 | 413,253 |
| For the three months ended · For the nine months ended | ||||
|---|---|---|---|---|
| Gross profit | September30, 2024 | September 30,2025 | September 30,2024 | September 30,2025 |
| (RMB in thousands) · (RMB in thousands) | ||||
| Central laboratory channel | 33,262 | 30,126 | 108,688 | 98,254 |
| In-hospital channel | 46,580 | 37,925 | 129,830 | 128,310 |
| Pharma research and development channel | 12,004 | 30,793 | 34,460 | 77,784 |
| Total gross profit | 91,846 | 98,844 | 272,978 | 304,348 |
| For the three months ended · For the nine months ended | ||||
|---|---|---|---|---|
| Share-based compensation expenses | September30, 2024 | September 30,2025 | September 30,2024 | September 30,2025 |
| (RMB in thousands) · (RMB in thousands) | ||||
| Cost of revenues | 289 | 301 | 1,349 | 889 |
| Research and development expenses | 3,180 | 73 | 27,475 | 1,603 |
| Selling and marketing expenses | 1,917 | 624 | 3,657 | 2,013 |
| General and administrative expenses | 4,732 | 2,831 | 115,129 | 6,249 |
| Total share-based compensation expenses | 10,118 | 3,829 | 147,610 | 10,754 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.